NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

Black Diamond Therapeutics logo
$1.44 -0.09 (-5.88%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.04%)
As of 11/17/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Black Diamond Therapeutics Stock (NASDAQ:BDTX)

Advanced

Key Stats

Today's Range
$1.39
▼
$1.53
50-Day Range
$1.44
▼
$2.10
52-Week Range
$1.39
▼
$4.06
Volume
645,968 shs
Average Volume
913,851 shs
Market Capitalization
$82.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Moderate Buy

Company Overview

Black Diamond Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them.

Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics conducts research and clinical development with the goal of addressing cancer mutations that may not be served by existing treatments.

AI Generated. May Contain Errors.

Black Diamond Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

BDTX MarketRank™: 
2.278295605855 of 5 stars

Black Diamond Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 540th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Black Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Black Diamond Therapeutics has a consensus price target of $11.00, representing about 663.9% upside from its current price of $1.44.

  • Amount of Analyst Coverage

    Black Diamond Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Black Diamond Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.72) to ($1.01) per share.

  • Price to Book Value per Share Ratio

    Black Diamond Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.80% of the float of Black Diamond Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Black Diamond Therapeutics has a short interest ratio ("days to cover") of 4.87.
  • Change versus previous month

    Short interest in Black Diamond Therapeutics has recently increased by 2.07%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Black Diamond Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Black Diamond Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Black Diamond Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • Search Interest

    Only 1 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.29% of the stock of Black Diamond Therapeutics is held by insiders.

  • Percentage Held by Institutions

    95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Black Diamond Therapeutics' insider trading history.
Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDTX Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

BDTX Stock Analysis - Frequently Asked Questions

Black Diamond Therapeutics' stock was trading at $2.43 at the start of the year. Since then, BDTX stock has decreased by 40.7% and is now trading at $1.44.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08.

Black Diamond Therapeutics (BDTX) raised $180 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 10,586,316 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Black Diamond Therapeutics' top institutional shareholders include Marshall Wace LLP (2.05%), State Street Corp (1.64%), Goldman Sachs Group Inc. (1.20%) and AWM Investment Company Inc. (1.13%).
View institutional ownership trends
.

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Cabaletta Bio (CABA), NVIDIA (NVDA), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Jefferies Global Healthcare Conference
11/19/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BDTX
CIK
1701541
Fax
N/A
Employees
21
Year Founded
2017

Price Target and Rating

High Price Target
$14.00
Low Price Target
$8.00
Potential Upside/Downside
+663.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$22.37 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.66%
Return on Assets
-28.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.92
Quick Ratio
6.92

Sales & Book Value

Annual Sales
$70 million
Price / Sales
1.18
Cash Flow
$0.50 per share
Price / Cash Flow
2.90
Book Value
$1.53 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
57,470,000
Free Float
52,129,000
Market Cap
$82.76 million
Optionable
Optionable
Beta
3.48

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:BDTX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners